Frontier Medicines’ Post

Drug Discovery Services Market Latest Statistics 2024 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/dtcN7Umn The size of global drug discovery services market in terms of revenue was estimated to be worth $20.6 billion in 2023 and is poised to reach $41.3 billion by 2028, growing at a CAGR of 14.9% from 2023 to 2028 Companies From the Market Enanta Pharmaceuticals NGM Biopharmaceuticals Biocytogen XtalPi Inc. NanoCellect Biomedical, Inc.    X-Chem, Inc. FUJIFILM Cellular Dynamics, Inc Sygnature Discovery BPS Bioscience Inc. Iambic Therapeutics Carmot Therapeutics, Inc. Active Motif The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology Structure Therapeutics   Antheia, Inc. Anima Biotech Genesis Therapeutics Reaction Biology Kallyope Ligand Pharmaceuticals      Remix Therapeutics o2h discovery NETZSCH Premier Technologies, LLC   Terray Therapeutics  Seismic Therapeutic Charnwood Discovery Flare Therapeutics Kumquat Biosciences Inc.      Plexium ACEA Biosciences AnaSpec Zephyr AI    Eurofins DiscoverX  Neomorph, Inc. Calibr-Skaggs Institute for Innovative Medicines      GemPharmatech MBL International Corporation   Neuron23 Cajal Neuroscience   Belharra Therapeutics

VISCHER advised HAYA Therapeutics, a Swiss biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics, which announced a multi-year agreement with Eli Lilly and Company to apply Haya’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. The partners will identify multiple regulatory genome derived RNA-based drug targets to address these chronic conditions. Vischer advised Haya Therapeutics on the Swiss legal aspects of the transaction. Cooley LLP acted as lead counsel in this transaction. The Vischer team included corporate / M&A partner Christian Wyss (pictured), Pauline Pfirter (senior associate, corporate / M&A), Lukas Wendt (associate, corporate / M&A), Ariane Cottiati (junior associate corporate / M&A) and Celine Kappler (junior associate, corporate / M&A). Read the full article >> https://lnkd.in/dsZ3CwZA #Legalcommunitych #legaladvisor #collaboration

Drug Discovery Services Market Worth $41.3 billion by 2028 🔵𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐑𝐄𝐄 𝐒𝐚𝐦𝐩𝐥𝐞:https://lnkd.in/diXdYs_N The global drug discovery services market in terms of revenue was estimated to be worth $20.6 billion in 2023 and is poised to reach $41.3 billion by 2028, growing at a CAGR of 14.9% from 2023 to 2028. 🔵 𝐌𝐚𝐢𝐧 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: X-Chem, Inc. Quantori NanoCellect Biomedical, Inc.      FUJIFILM Cellular Dynamics, Inc    Iambic Therapeutics  Sygnature Discovery XtalPi Inc. Skyhawk Therapeutics    BPS Bioscience Inc.     Biocytogen  Anima Biotech   The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology Active Motif Reaction Biology Kallyope NETZSCH Premier Technologies, LLC       o2h discovery      Structure Therapeutics     Terray Therapeutics Remix Therapeutics       Eureka Therapeutics, Inc    Neomorph, Inc.      Charnwood Discovery   ACEA Biosciences  Plexium   AnaSpec Eurofins DiscoverX HTG Molecular Diagnostics       Calibr-Skaggs Institute for Innovative Medicines        MBL International Corporation     GemPharmatech Belharra Therapeutics HotSpot Therapeutics, Inc.   Neuron23       Jubilant Biosys Limited        Cajal Neuroscience NanoImaging Services  Skills Alliance abcam BenevolentAI 

Can you go from idea to drug candidate in one year? At Gubra, we constantly pursue novel approaches to advance and enable smarter and faster peptide drug discovery. Therefore, we were eager to get started when presented with this exciting challenge “can you make a drug candidate that ticks all the boxes, i.e. potent in vivo efficacy, a long half-life and excellent physicochemical properties. Do it within a year!” With this aim, we exploited our innovative ML-based peptide drug discovery platform ‘streaMLine’ and demonstrated how the platform effectively facilitates accelerated development of novel peptide-based therapeutics. Did we succeed? Yes! And it has been a fun ride! Definitely some ups and downs along the way and many lengthy discussions with the project team. A total of 2688 peptides were synthesized, screened, and analyzed using the ML-guided approach to map out a solution space for generating GLP-1R agonists derived from the secretin backbone. We are happy to present the inner workings of our streaMLine drug discovery platform in the Journal of Medicinal Chemistry Kudos to the amazing team, (Jens Christian Nielsen,Claudia U. Hjørringgaard,Mads Mørup Nygaard, Anita Wester, Lisbeth Elster, Trine Porsgaard, Randi Bonke Mikkelsen, Silas Anselm Rasmussen, Andreas Nygaard Madsen, Morten Schlein, Niels Vrang, Kristoffer Rigbolt). Thanks for making this project a success. If you are into some light summer reading, you can find the full story here: (https://lnkd.in/dsAm7UHE) #drugdiscovery #pushingboundaries #speed #quality

We are delighted to introduce Dr. Jeff Lin, PhD, a passionate and innovative bioanalytical scientist from Genentech, who will be presenting at the Applied Pharmaceutical Analysis (APA) 2024 Conference. Dr. Lin's talk, titled "Characterizing In Vivo Stability of Large Molecule Conjugates Using Complementary Bioanalytical Tools," is set to be a highlight of the event. As a Senior Scientist in the large molecule bioanalytical group at Genentech, Dr. Lin plays a critical role in supporting preclinical pharmacology analysis. His expertise spans various analytical techniques such as mass spectrometry, capillary electrophoresis, and plate-based immunoassays. With a current focus on oligonucleotide-based modalities, Dr. Lin’s experience also includes antibodies/bispecifics, enzyme replacement therapies, and Fab conjugates. His science-driven approach has led to multiple publications in top-tier peer-reviewed journals, including the Journal of the American Chemical Society. In his upcoming talk, Dr. Lin will explore the challenges and solutions related to the in vivo stability of novel large molecule conjugates, including antibody-oligonucleotide and Fab conjugates. He will present a multi-pronged approach using LC-MS and capillary electrophoresis-based methods to characterize and quantify biotransformation liabilities. This comprehensive analysis will address the translatability of in vitro findings to in vivo conditions, providing critical insights into linker deconjugation, clipping, and amino acid level modifications. Why is this important? Understanding the in vivo stability of large molecule conjugates is essential for the development of effective biotherapeutics, especially for targeting "undruggable" conditions. Dr. Lin's research offers valuable strategies to overcome these challenges, ensuring better therapeutic outcomes. 📅 Date: October 7-9, 2024 📍 Location: Bristol Myers Squibb, Cambridge, MA  🔗 For more details and registration, visit the APA 2024 Conference website - https://lnkd.in/ecN6EQr Engage with leading experts, delve into cutting-edge research, and be part of the future of pharmaceutical analysis.  #APA2024 #PharmaceuticalAnalysis #Bioanalysis #Biotherapeutics #DrugDevelopment Ju Liu, Jonathan Josephs, John Williams, Jing Tu, Christopher Kochansky, Hiroshi Sugimoto, Hongying Gao, Lina Luo, Zachary Parsons, Yu Tian, Jeff Lin, Nagendra Chemuturi Ph.D., MBA, Aihua Liu

🚀 Registration Now Open for the Oligonucleotide Therapeutics Xchange - Maryland 2024! 🚀 We are thrilled to share that registration is now open for hubXchange's Oligonucleotide Therapeutics Xchange Maryland 2024! This event will convene leading executives from the pharma and biotech sectors to tackle and find solutions for the critical challenges in Oligonucleotide Therapeutics. 📅 Date: Wednesday, October 30, 2024 🕗 Time: 8:00 AM - 6:15 PM 📍 Location: Maryland Join us to stay at the forefront of Oligonucleotide Therapeutics innovation and connect with fellow industry leaders. Don’t miss out—register today and get your Complimentary Pass! https://lnkd.in/eyChA_wt 🔎 Why Attend hubXchange? Take advantage of a unique platform that promotes knowledge exchange and industry connections. 🗣🔬 Featuring Industry Experts: Weiguo Zhai, Senior Director, R&D Analytical Sciences, BioPharmaceutical Development, AstraZeneca Xiaoyong Lu, M.S. Ph.D., Director of Oligonucleotide and Genetic Medicine, Eli Lilly and Company Antonio DiGiandomenico, Senior Director, AstraZeneca Jimmy Weterings, VP, Research RNA Therapeutics & Delivery, Sirnaomics Jeremy Little, Director of Custom Oligonucleotides, ChemGenes Trishul Shah, Director Business Development, Head of Sales North America, PolyPeptide Group Jeremy Little, Director of Custom Oligonucleotides, ChemGenes David Brown, Director, RNAimmune David Blackmon, Director, Alcyone Therapeutics Inc. Our Partners: 🤝 ChemGenes 🤝 PolyPeptide Group 💊 Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #OligonucleotideTherapeutics #Pharma #Biotech #hubXchange #Networking #Innovation #MarylandEvent #DrugDevelopment #RNAtherapeutics #GeneticMedicine #Biopharma #Pharmaceuticals #Biotechnology #LifeSciences #MedicalResearch #HealthcareInnovation #BiotechCommunity #ScientificConference #Therapeutics #BiotechInnovation #PharmaConference #ClinicalResearch #DrugDelivery #NewModalities #OligonucleotideDiscovery #PharmaNetworking #PharmaEvents #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass

In addition to its review of 'Molecule of the Month', Drug Hunter also publishes articles that examine drug discovery research trends, and industry targets & tech discussed at leading scientific conferences. Enjoy this look-back at the most popular ones in 2023. #biopharma #pharma #research #drugdiscovery #drugdevelopment #lifesciences #researchanddevelopment

Synendos Therapeutics AG is excited to announce the publication of the latest article written by Andrea Chicca and Jürg Gertsch, “CNS Drug Discovery in Academia: Where Basic Research Meets Innovation“, now available on #ChemBioChem: https://lnkd.in/eZ4mcQ7D In this article, they provide their perspective on the interaction between academia and drug discovery based on a 12-year experience with the NCCR-TransCure project, from which Synendos Therapeutics AG originated. Read the full article and discover how innovative research in academia can inspire drug discovery. #Biotech #Academia #drugdiscovery #ChemBioChem #SERI #endocannabinoidsystem

BridGene Biosciences, Inc. co-founders Ping Cao and Irene Yuan are featured in the current issue of Drug Development & Delivery. In the realm of drug discovery, two primary approaches take center stage: Phenotypic Drug Discovery (PDD) and Target-Based Drug Discovery (TDD). Each approach offers unique advantages and has contributed significantly to the development of novel therapeutic agents. In this context, BridGene’s Chemoproteomic platform IMTAC™ (Isobaric Mass-Tagged Affinity Characterization) has emerged as one of the most powerful technologies to seamlessly merge the benefits of PDD and TDD. By utilizing IMTAC, re­searchers can efficiently analyze the interactions between poten­tial drug compounds and cellular proteins, allowing for the identification and validation of target molecules associated with specific phenotypic responses. https://lnkd.in/e3jbvghd

Register for the FOP Drug Development Forum in June in Stockholm, Sweden (or virtually). With the first-ever treatment for FOP approved in select countries and five active FOP clinical trials, there is still an abundance of preclinical research with the potential to be translated into safe and effective new medicines. Molecules advancing drug discovery, advanced therapeutic modalities and new technologies must continually be explored for their potential to treat understudied signs and symptoms of FOP. The DDF brings together biotech and pharmaceutical companies, academic researchers and clinician scientists to collaborate and advance FOP research. It's an opportunity to discuss emerging FOP data and highlight gaps in our understanding of FOP disease pathogenesis that could offer new therapeutic options. Learn more and register: ifopa.org/2024_fop_ddf